Improgan, a compound related to H-2 and H-3 antagonists, induces antinocice
ption in rodents after intraventricular administration. Characteristics of
improgan and its congeners include: (a) morphine-like antinociception on th
ermal and mechanical tests in two species; (b) no impairment of motor coord
ination or locomotor activity; (c) evidence for a novel, nonopioid mechanis
m that is independent of known histamine receptors; (d) lack of tolerance w
ith dairy dosing; and (e) unique structure-activity relationships (SARs). P
resently, the antinociceptive activity of several new derivatives of improg
an was investigated in rats. Among compounds similar to burimamide, VUF4577
(possessing a two-carbon side chain) and VUF4582 (an N-phenyl derivative o
f VUF4577) induced complete, dose- and time-dependent antinociception on th
e hot-plate and tail-flick tests with no behavioral side effects. These com
pounds (with ED50 values of 71-117 nmol) were approximately twice as potent
as burimamide itself (a four-carbon derivative). Two other derivatives in
which the thiourea group (C=S, known to cause human toxicity) was replaced
by either nitroethene (C=CH-NO2, VUF5405) or urea (C=O, VUF5407) also showe
d effective, potent antinociception on both assays. The latter compound is
the most potent improgan-like drug discovered to date (ED50 = 71 nmol). Fur
thermore, positional isomers of antinociceptive compounds either lacked act
ivity (VUF5394) or induced toxicity (VUF5393), revealing a high degree of p
harmacological specificity. Although the mechanism of improgan antinocicept
ion re mains unknown, the present results show promise for the further deve
lopment of safe, effective, and potent pain-relieving compounds. (C) 1999 E
lsevier Science Inc.